Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies

摘要: The identification of somatic driver mutations in human samples has allowed for the development a molecular classification melanoma. Recent breakthroughs treatment metastatic melanoma have arisen as result these significant new insights into biology disease, particularly inhibitors activating BRAFV600E mutations. In this article roles several known to be involved malignant transformation melanocytes are reviewed including BRAF, PTEN, NRAS, ckit, and p16 well some emerging cutaneous uveal bench bedside collaborations that resulted discoveries summarized, potential therapeutic strategies target specific patient subsets discussed.